DESLEM,DESQUOTE,DESTIXINE, DESVENLAFAXINE AGH,DESVENLAFAXINE AGHL, DESVENLAFAXINE ALEMBIC, DESVENLAFAXINE APL, DESVENLAFAXINE APPL, DESVOLIN (Alembic Pharmaceuticals Australia Pty Ltd)
Product name
DESLEM,DESQUOTE,DESTIXINE, DESVENLAFAXINE AGH,DESVENLAFAXINE AGHL, DESVENLAFAXINE ALEMBIC, DESVENLAFAXINE APL, DESVENLAFAXINE APPL, DESVOLIN
Date registered
Evaluation commenced
Decision date
Approval time
137 (255 working days)
Active ingredients
Desvenlafaxine
Registration type
New generic medicine
Indication
DESLEM,DESQUOTE,DESTIXINE, DESVENLAFAXINE AGH,DESVENLAFAXINE AGHL, DESVENLAFAXINE ALEMBIC, DESVENLAFAXINE APL, DESVENLAFAXINE APPL, DESVOLIN is indicated for the treatment of major depressive disorder, including the prevention of relapse.
DESLEM,DESQUOTE,DESTIXINE, DESVENLAFAXINE AGH,DESVENLAFAXINE AGHL, DESVENLAFAXINE ALEMBIC, DESVENLAFAXINE APL, DESVENLAFAXINE APPL, DESVOLIN is not indicated for paediatric use.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine